论文部分内容阅读
目的了解不同质子泵抑制剂根除幽门螺杆菌(Hp)的疗效。方法 60例Hp阳性患者随机分成两组:①ECA组(n=25):埃索美拉唑20mg,每天2次,克拉霉素0.25mg,每天2次,阿莫西林1000mg,每天2次;②LCA组(n=35):兰索拉唑30mg,每天2次,克拉霉素0.25mg,每天2次,阿莫西林1000mg,每天2次。治疗结束后4周复查尿素呼气试验(UBT)。结果评价60例患者,按意向治疗分析,ECA、LCA两组根除率分别为72.00%、74.28%;按完成治疗分析,ECA、LCA两组根除率分别为81.81%、83.87%,差异均无显著性(P>0.05)。结论埃索美拉唑与兰索拉唑为基础的三联疗法对Hp根除治疗差异无显著性。
Objective To understand the efficacy of different proton pump inhibitors in eradicating Helicobacter pylori (Hp). Methods 60 patients with Hp positive were randomly divided into two groups: ①ECA group (n = 25): esomeprazole 20mg twice a day, clarithromycin 0.25mg twice a day, amoxicillin 1000mg twice a day; ②LCA Group (n = 35): Lansoprazole 30 mg twice daily, clarithromycin 0.25 mg twice daily, amoxicillin 1000 mg twice daily. The urea breath test (UBT) was reviewed 4 weeks after the end of treatment. Results According to the intent-to-treat analysis, the eradication rates of ECA and LCA were 72.00% and 74.28% respectively. According to the completion of treatment, the eradication rates of ECA and LCA were 81.81% and 83.87%, respectively, with no significant difference (P> 0.05). Conclusions There is no significant difference between Hesperidin and Hp eradication therapy with esomeprazole and lansoprazole - based triple therapy.